CD274 and diffuse large B-cell lymphoma: A phase II study of anti-PD-L1 antibody durvalumab, either in combination with R-CHOP (arm A) or with lenalidomide and R-CHOP (arm B) has been recruiting patients with previously untreated high-risk DLBCL (NCT03003520).